	US 12,085,573 B2
	Means and methods applying sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia within a certain time period
Martin Hund, Horw (CH); and Maria Schoedl, Baierbrunn (DE)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Dec. 19, 2014, as Appl. No. 14/576,944.
Application 14/576,944 is a continuation of application No. PCT/EP2013/063115, filed on Jun. 24, 2013.
Claims priority of application No. 12173886 (EP), filed on Jun. 27, 2012; and application No. 12183508 (EP), filed on Sep. 7, 2012.
Prior Publication US 2015/0338415 A1, Nov. 26, 2015
Int. Cl. G01N 33/68 (2006.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01)

CPC G01N 33/689 (2013.01) [G16H 50/30 (2018.01); G16H 50/70 (2018.01); G01N 2333/475 (2013.01); G01N 2333/515 (2013.01); G01N 2333/71 (2013.01); G01N 2333/912 (2013.01); G01N 2800/368 (2013.01)]

3 Claims

1. A method for identifying and managing a pregnant subject that will not develop preeclampsia for two weeks, comprising:

a) determining the amounts of the biomarkers soluble FMS-Like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (P1GF) by contacting the biomarkers with an antibody or labeled antibody and detecting the presence of complexes formed between the antibody or labeled antibody and the biomarkers in a sample of said subject, wherein said detecting comprises detecting the complexes by electrochemiluminescence;

b) calculating a ratio from said amounts of sFlt-1 and PIGF determined in the sample in step (a);

c) comparing the ratio with a reference value, said reference value is 38+/−20%; and

d) based on the comparison of step c), identifying a pregnant subject that will not develop preeclampsia for two weeks if the value of the ratio is identical or decreased compared to the reference, and

e) managing said subject by ambulant monitoring.